{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T07:20:15Z","timestamp":1777706415198,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T00:00:00Z","timestamp":1523577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ALK-Abell\u00f3 A\/S"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.anai.2018.04.007","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T02:31:51Z","timestamp":1523500311000},"page":"105-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration"],"prefix":"10.1016","volume":"121","author":[{"given":"David I.","family":"Bernstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Kleine-Tebbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Jose A.","family":"Bardelas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon L.","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorte","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bodil","family":"Svanholm Fogh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"Nolte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2018.04.007_bib0010","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jaci.2015.06.036","article-title":"Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized double-blind, placebo-controlled phase III trial","volume":"137","author":"Demoly","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.04.007_bib0015","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jaci.2014.03.019","article-title":"Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Mosbech","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.04.007_bib0020","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.jaci.2016.06.044","article-title":"Efficacy of house dust mite SLIT-tablet in North American adolescents and adults in a randomized, placebo-controlled trial","volume":"138","author":"Nolte","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.04.007_bib0025","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.jaci.2014.12.1911","article-title":"Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber","volume":"135","author":"Nolte","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.04.007_bib0030","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1001\/jama.2016.3964","article-title":"Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial","volume":"315","author":"Virchow","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.anai.2018.04.007_bib0035","series-title":"Global strategy for asthma management and prevention, Global Initiative for Asthma (GINA)","year":"2017"},{"key":"10.1016\/j.anai.2018.04.007_bib0040","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/all.12074","article-title":"Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects","volume":"68","author":"Nelson","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2018.04.007_bib0045","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2222.2008.03152.x","article-title":"Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis","volume":"39","author":"Malling","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2018.04.007_bib0050","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/00325481.2017.1302306","article-title":"A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice","volume":"129","author":"Bernstein","year":"2017","journal-title":"Postgrad Med"},{"key":"10.1016\/j.anai.2018.04.007_bib0055","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2010.09.034","article-title":"Allergen immunotherapy: a practice parameter third update","volume":"127","author":"Cox","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.04.007_bib0060","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/all.12198","article-title":"Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach","volume":"68","author":"Savi","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2018.04.007_bib0065","series-title":"Full Prescribing Information, Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA","author":"ODACTRA (House dust mite allergen extract tablet for sublingual use)","year":"2017"},{"key":"10.1016\/j.anai.2018.04.007_bib0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000444016","article-title":"Fractionation of source materials leads to high reproducibility of SQ HDM SLIT-tablets","volume":"169","author":"Henmar","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.anai.2018.04.007_bib0075","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jaci.2013.03.039","article-title":"Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language","volume":"132","author":"Passalacqua","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.04.007_bib0080","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40271-017-0217-0","article-title":"Development of a report card for identifying local sublingual immunotherapy events in clinical trials","volume":"10","author":"Norquist","year":"2017","journal-title":"Patient"},{"key":"10.1016\/j.anai.2018.04.007_bib0085","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/WOX.0b013e3181c6c379","article-title":"Sub-lingual immunotherapy: World Allergy Organization position paper 2009","volume":"2","author":"Canonica","year":"2009","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.anai.2018.04.007_bib0090","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1081-1206(10)60259-1","article-title":"Comparison of allergen immunotherapy practice patterns in the United States and Europe","volume":"103","author":"Cox","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2018.04.007_bib0095","doi-asserted-by":"crossref","first-page":"AB218","DOI":"10.1016\/j.jaci.2013.12.780","article-title":"Efficacy of the short-ragweed sublingual immunotherapy tablet MK-3641 in monosensitized and polysensitized subjects","volume":"133","author":"Bernstein","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.04.007_bib0100","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/ACI.0b013e32834c229e","article-title":"Risk factors for systemic reactions to allergen immunotherapy","volume":"11","author":"Iglesias-Cadarso","year":"2011","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.04.007_bib0105","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1365-2222.2010.03688.x","article-title":"Specific immunotherapy in asthma: efficacy and safety","volume":"41","author":"Passalacqua","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2018.04.007_bib0110","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/all.12560","article-title":"Safety of sublingual immunotherapy Timothy grass tablet in subjects with allergic rhinitis with or without conjunctivitis and history of asthma","volume":"70","author":"Maloney","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2018.04.007_bib0115","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.anai.2014.04.018","article-title":"Safety and tolerability of a short ragweed sublingual immunotherapy tablet","volume":"113","author":"Nolte","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2018.04.007_bib0120","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-144-4-200602210-00007","article-title":"Brief communication: better ways to question patients about adverse medical events: a randomized, controlled trial","volume":"144","author":"Bent","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.anai.2018.04.007_bib0125","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/014107689108400612","article-title":"Spontaneous adverse drug reaction reporting vs event monitoring: a comparison","volume":"84","author":"Fletcher","year":"1991","journal-title":"J R Soc Med"},{"key":"10.1016\/j.anai.2018.04.007_bib0130","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2165\/00002018-200528110-00006","article-title":"Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods","volume":"28","author":"Wernicke","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.anai.2018.04.007_bib0135","doi-asserted-by":"crossref","unstructured":"Nolte H., Bernstein D.I., Sussman G.L., et\u00a0al. Impact of adverse event solicitation on the safety profile of SQ house dust mite sublingual immunotherapy tablet [Epub ahead of print]. J Allergy Clin Immunol Pract. doi:10.1016\/j.jaip.2018.01.037.","DOI":"10.1016\/j.jaip.2018.01.037"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112061830293X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112061830293X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:18:58Z","timestamp":1761052738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108112061830293X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S108112061830293X"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2018.04.007","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2018.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}